$CNTA
Centessa Pharmaceuticals plc Stock $cnta

$cnta Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000184790324000054 Filed on March 28, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue		$6.853M	$6.853M
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$12.32M	$53.73M
YoY Change		-10.55%	-2.66%
% of Gross Profit
Research & Development	$22.65M	$29.72M	$124.4M
YoY Change	-30.99%	6.76%	-19.78%
% of Gross Profit
Depreciation & Amortization	$240.0K	$250.0K	$810.0K
YoY Change	169.66%	594.44%	518.32%
% of Gross Profit
Operating Expenses	$22.65M	$42.03M	$178.1M
YoY Change	-30.99%	1.03%	14.86%
Operating Profit	-$36.09M		-$171.3M
YoY Change	-26.16%		-19.31%
Interest Expense	$2.529M	$363.0K	$570.0K
YoY Change	7.85%	-116.77%	-108.1%
% of Operating Profit
Other Income/Expense, Net	-$1.537M	-$878.0K	-$5.428M
YoY Change	14.19%	1154.29%	-331.77%
Pretax Income	-$37.57M	-$35.69M	-$176.1M
YoY Change	-24.93%	-18.58%	-18.81%
Income Tax	$481.0K	$1.144M	-$25.06M
% Of Pretax Income
Net Earnings	-$38.05M	-$36.84M	-$151.1M
YoY Change	-24.98%	-14.68%	-30.12%
Net Earnings / Revenue		-537.53%	-2204.65%
Basic Earnings Per Share	-$0.38		-$1.57
Diluted Earnings Per Share	-$0.38	-$0.38	-$1.57
COMMON SHARES
Basic Shares Outstanding	100.3M shares	97.63M shares	96.18M shares
Diluted Shares Outstanding	99.89M shares		96.18M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$230.2M	$256.5M	$256.5M
YoY Change	-33.52%	-34.83%	-34.83%
Cash & Equivalents	$118.2M	$128.0M
Short-Term Investments	$112.0M	$128.5M	$128.5M
Other Short-Term Assets	$1.797M	$19.40M	$19.40M
YoY Change	-42.53%	492.94%	11.59%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$284.5M	$315.1M	$315.1M
YoY Change	-25.98%	-28.02%	-28.02%
LONG-TERM ASSETS
Property, Plant & Equipment	$952.0K	$12.95M	$12.95M
YoY Change	-21.9%	1008.99%	1008.99%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.883M	$32.20M	$32.20M
YoY Change	-68.82%	497.2%	497.2%
Total Long-Term Assets	$43.70M	$45.15M	$45.15M
YoY Change	123.73%	588.32%	588.32%
TOTAL ASSETS
Total Short-Term Assets	$284.5M	$315.1M	$315.1M
Total Long-Term Assets	$43.70M	$45.15M	$45.15M
Total Assets	$328.2M	$360.2M	$360.2M
YoY Change	-18.74%	-18.92%	-18.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.499M	$11.82M	$11.82M
YoY Change	-47.81%	-14.61%	-14.61%
Accrued Expenses	$19.94M	$27.46M	$27.46M
YoY Change	30.15%	12.06%	19.8%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$27.44M	$39.39M	$39.39M
YoY Change	-7.58%	2.73%	2.73%
LONG-TERM LIABILITIES
Long-Term Debt	$76.80M	$75.70M	$75.70M
YoY Change	7.26%	8.45%	8.45%
Other Long-Term Liabilities	$29.00K	$8.917M	$8.917M
YoY Change	-99.69%
Total Long-Term Liabilities	$76.83M	$84.62M	$84.62M
YoY Change	7.3%	21.23%	21.23%
TOTAL LIABILITIES
Total Short-Term Liabilities	$27.44M	$39.39M	$39.39M
Total Long-Term Liabilities	$76.83M	$84.62M	$84.62M
Total Liabilities	$113.0M	$124.0M	$124.0M
YoY Change	2.18%	14.67%	14.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$791.0M	-$752.9M
YoY Change	21.21%	25.09%
Common Stock	$277.0K	$273.0K
YoY Change	4.14%	3.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$215.2M	$236.2M	$236.2M
YoY Change
Total Liabilities & Shareholders Equity	$328.2M	$360.2M	$360.2M
YoY Change	-18.74%	-18.92%	-18.92%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$38.05M	-$36.84M	-$151.1M
YoY Change	-24.98%	-14.68%	-30.12%
Depreciation, Depletion And Amortization	$240.0K	$250.0K	$810.0K
YoY Change	169.66%	594.44%	518.32%
Cash From Operating Activities	-$37.29M	-$31.05M	-$160.3M
YoY Change	-22.06%	-39.78%	-20.05%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$29.00K	$169.0K
YoY Change	-100.0%	-95.55%	-85.14%
Acquisitions
YoY Change
Other Investing Activities	$16.76M	-$18.24M	-$126.8M
YoY Change	-119.43%	-8956.8%	61470.39%
Cash From Investing Activities	$16.76M	-$18.27M	-$127.0M
YoY Change	-119.41%	3997.31%	13541.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$21.12M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$10.49M	6.357M	21.12M
YoY Change		7042.7%	4520.79%
NET CHANGE
Cash From Operating Activities	-$37.29M	-31.05M	-160.3M
Cash From Investing Activities	$16.76M	-18.27M	-127.0M
Cash From Financing Activities	$10.49M	6.357M	21.12M
Net Change In Cash	-$9.812M	-42.97M	-266.2M
YoY Change	-92.66%	-17.24%	32.16%
FREE CASH FLOW
Cash From Operating Activities	-$37.29M	-$31.05M	-$160.3M
Capital Expenditures	$0.00	$29.00K	$169.0K
Free Cash Flow	-$37.29M	-$31.08M	-$160.5M
YoY Change	-22.2%	-40.48%	-20.41%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001847903
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40445
CY2023	dei	Entity Registrant Name EntityRegistrantName	CENTESSA PHARMACEUTICALS PLC
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1612294
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	3rd Floor
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	1 Ashley Road
CY2023	dei	Entity Address Address Line3 EntityAddressAddressLine3	Altrincham
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Cheshire
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	WA14 2DT
CY2023	dei	Entity Address Country EntityAddressCountry	GB
CY2023	dei	Country Region CountryRegion	+1
CY2023	dei	City Area Code CityAreaCode	617)
CY2023	dei	Local Phone Number LocalPhoneNumber	468-5770
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	310787000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	100305850	shares
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	128030000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	393644000	usd
CY2023	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	10476000	usd
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	244000	usd
CY2022	us-gaap	Interest Expense InterestExpense	7277000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	128519000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	0	usd
CY2023Q4	cnta	Tax Incentive Receivable Current TaxIncentiveReceivableCurrent	37818000	usd
CY2022Q4	cnta	Tax Incentive Receivable Current TaxIncentiveReceivableCurrent	24166000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	20725000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	19937000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	315092000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	437747000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1039000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1168000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	11914000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	29647000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	3512000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2554000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1880000	usd
CY2023Q4	us-gaap	Assets Assets	360246000	usd
CY2022Q4	us-gaap	Assets Assets	444307000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11815000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	13836000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	27570000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24502000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	39385000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	38338000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	75700000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	69800000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8888000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	29000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	usd
CY2023Q4	us-gaap	Liabilities Liabilities	124002000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	108138000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.002
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.002
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	152500000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	152500000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	98774827	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	98774827	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	94843391	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	94843391	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	273000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	265000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	987423000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	939261000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1493000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1497000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-752945000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-601860000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	236244000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	336169000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	360246000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	444307000	usd
CY2023	us-gaap	Revenues Revenues	6853000	usd
CY2022	us-gaap	Revenues Revenues	0	usd
CY2023	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	124405000	usd
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	155083000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	53731000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	55200000	usd
CY2023	cnta	Asset Acquisition Contingent Consideration Liability Gain Loss From Change In Fair Value AssetAcquisitionContingentConsiderationLiabilityGainLossFromChangeInFairValue	0	usd
CY2022	cnta	Asset Acquisition Contingent Consideration Liability Gain Loss From Change In Fair Value AssetAcquisitionContingentConsiderationLiabilityGainLossFromChangeInFairValue	1980000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-171283000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-212263000	usd
CY2023	us-gaap	Interest Expense InterestExpense	9906000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5428000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-176141000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-216954000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-25056000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-747000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-151085000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-216207000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1700000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2185000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	400000	usd
CY2023	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1290000	usd
CY2022	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-148095000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-218392000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.57
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.57
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.31
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.31
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	96177578	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	96177578	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	93400513	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	93400513	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	491554000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	37748000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	799000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24965000	usd
CY2022	cnta	Share Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Units Aggregate Intrinsic Value Vested ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsAggregateIntrinsicValueVested	0	usd
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	505000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2185000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-216207000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	336169000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	20807000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-151085000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-216207000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	29392000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	24965000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	810000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	131000	usd
CY2023	cnta	Financial Instruments Change In Fair Value Gain Loss Net FinancialInstrumentsChangeInFairValueGainLossNet	-5900000	usd
CY2022	cnta	Financial Instruments Change In Fair Value Gain Loss Net FinancialInstrumentsChangeInFairValueGainLossNet	3920000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-26529000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2857000	usd
CY2023	cnta	Increase Decrease In Tax Incentive Receivables IncreaseDecreaseInTaxIncentiveReceivables	12092000	usd
CY2022	cnta	Increase Decrease In Tax Incentive Receivables IncreaseDecreaseInTaxIncentiveReceivables	11711000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1364000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3732000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1883000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2722000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6351000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-797000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	6261000	usd
CY2023	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	28000	usd
CY2022	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	173000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-160342000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-200546000	usd
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	264910000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	138075000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	169000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1137000	usd
CY2023	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	usd
CY2022	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-206000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-127004000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-931000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	20807000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	310000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	718000	usd
CY2023	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	usd
CY2022	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-261000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21117000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	457000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	615000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-418000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-265614000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-201438000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	393644000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	595082000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	128030000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	393644000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	9906000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	7277000	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	2943000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	1299000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	1178000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	0	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	9711000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023	cnta	Stock Issued To Settle Contingent Value Rights StockIssuedToSettleContingentValueRights	0	usd
CY2022	cnta	Stock Issued To Settle Contingent Value Rights StockIssuedToSettleContingentValueRights	39680000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-752900000	usd
CY2023Q4	cnta	Cash And Cash Equivalents And Short Term Investments CashAndCashEquivalentsAndShortTermInvestments	256500000	usd
CY2023	cnta	Cash And Cash Equivalents At Carrying Value Sufficient Funding Term CashAndCashEquivalentsAtCarryingValueSufficientFundingTerm	P12M
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and short-term investments. The Company’s cash, cash equivalents and short-term investments are held by financial institutions primarily in the United States and the United Kingdom. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institutions are financially sound, and accordingly, the Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div>
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no effect on previously reported net loss or comprehensive loss.</span></div>
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	800000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2800000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. Significant areas that require management’s estimates include accrued research and development expenses, the note purchase agreement, share-based compensation, leases and tax-related matters.</span></div>
CY2023	us-gaap	Depreciation Depreciation	298000	usd
CY2022	us-gaap	Depreciation Depreciation	131000	usd
CY2023	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	500000	usd
CY2023Q4	cnta	Note Purchase Agreement Milestone Payment Percent Of Aggregate Principal Amount Issued NotePurchaseAgreementMilestonePaymentPercentOfAggregatePrincipalAmountIssued	0.30
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	24300000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	12600000	usd
CY2023Q4	cnta	Research And Development Tax Credit Limitation Expenditure On Employees Multiple ResearchAndDevelopmentTaxCreditLimitationExpenditureOnEmployeesMultiple	3
CY2023	cnta	Research And Development Tax Credit Limitation Expenditure On Employees Additional Value ResearchAndDevelopmentTaxCreditLimitationExpenditureOnEmployeesAdditionalValue	20000	eur
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.04
CY2023	cnta	Defined Contribution Plan Minimum Contribution Percent DefinedContributionPlanMinimumContributionPercent	0.08
CY2023	cnta	Defined Contribution Plan Minimum Employer Contribution Percent DefinedContributionPlanMinimumEmployerContributionPercent	0.04
CY2023	cnta	Defined Contribution Plan Minimum Employee Contribution Percent DefinedContributionPlanMinimumEmployeeContributionPercent	0.04
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	600000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	700000	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18328530	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17093177	shares
CY2022Q4	cnta	Prepaid Research And Development Costs PrepaidResearchAndDevelopmentCosts	11321000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1651000	usd
CY2023Q4	cnta	Prepaid Research And Development Costs PrepaidResearchAndDevelopmentCosts	16123000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	2788000	usd
CY2023Q4	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	1330000	usd
CY2022Q4	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	2557000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1621000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3271000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	20725000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	19937000	usd
CY2023Q4	cnta	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	18814000	usd
CY2022Q4	cnta	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	10795000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6733000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7264000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1072000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4171000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	112000	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1582000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	839000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	690000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	27570000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24502000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1501000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1332000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	462000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	164000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1039000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1168000	usd
CY2023	us-gaap	Debt Instrument Term DebtInstrumentTerm	P6Y
CY2023	cnta	Debt Instrument Reference Rate DebtInstrumentReferenceRate	0.0775
CY2023	us-gaap	Long Term Debt Weighted Average Interest Rate Over Time LongTermDebtWeightedAverageInterestRateOverTime	0.130
CY2022	us-gaap	Long Term Debt Weighted Average Interest Rate Over Time LongTermDebtWeightedAverageInterestRateOverTime	0.096
CY2023	cnta	Milestone Payment Percent Of Aggregate Principal Amount Issued Under The Notes MilestonePaymentPercentOfAggregatePrincipalAmountIssuedUnderTheNotes	0.30
CY2023	cnta	Milestone Payment Period MilestonePaymentPeriod	P5Y
CY2023Q4	cnta	Cumulative Payments Under Note Purchase Agreement Including Interest CumulativePaymentsUnderNotePurchaseAgreementIncludingInterest	18700000	usd
CY2023Q4	cnta	Note Purchase Agreement Deductible Amount Due To Company NotePurchaseAgreementDeductibleAmountDueToCompany	100000000	usd
CY2023Q4	cnta	Note Purchase Agreement Deductible Amount Due To Company NotePurchaseAgreementDeductibleAmountDueToCompany	100000000	usd
CY2023	cnta	Note Purchase Agreement Percent Of Aggregate Outstanding Principal Amount Cash Balance Required NotePurchaseAgreementPercentOfAggregateOutstandingPrincipalAmountCashBalanceRequired	0.90
CY2023Q4	us-gaap	Purchase Obligation PurchaseObligation	61100000	usd
CY2023Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	45100000	usd
CY2023Q4	cnta	Purchase Obligation To Be Paid Year One Through Five PurchaseObligationToBePaidYearOneThroughFive	16000000	usd
CY2022Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P10Y
CY2022Q1	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	18922	sqft
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	1600000	usd
CY2023	cnta	Operating Lease Expense Year10 OperatingLeaseExpenseYear10	1900000	usd
CY2022Q1	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	700000	usd
CY2022Q1	cnta	Lessee Operating Lease Number Of Options To Extend LesseeOperatingLeaseNumberOfOptionsToExtend	1	option
CY2022Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	11900000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	9400000	usd
CY2023Q4	cnta	Sublease Agreement Term SubleaseAgreementTerm	P5Y
CY2023Q4	cnta	Number Of Square Feet To Sublease NumberOfSquareFeetToSublease	4242	sqft
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	11914000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8888000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	9393000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1197
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	1498000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	0	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	53000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	66000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	26000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	131000	usd
CY2023	us-gaap	Sublease Income SubleaseIncome	58000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	0	usd
CY2023	us-gaap	Lease Cost LeaseCost	1519000	usd
CY2022	us-gaap	Lease Cost LeaseCost	197000	usd
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	70197	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.41
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2092484	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	8.37
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1602000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	348000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1634000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	355000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1667000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	362000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1700000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	369000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1734000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Five Years LessorOperatingLeasePaymentsToBeReceivedFiveYears	376000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	7289000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Thereafter LessorOperatingLeasePaymentsToBeReceivedThereafter	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	15626000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	1810000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	6233000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	9393000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	505000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8888000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	29392000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24965000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14688996	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.88
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3542700	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.48
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	16069015	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.09
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	29000000.0	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	29000000.0	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	8417959	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.41
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y6M
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	13400000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	16069015	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	7.09
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y10M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	29000000.0	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	29000000.0	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	30700000	usd
CY2023Q4	us-gaap	Share Price SharePrice	7.96
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	29000000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	29000000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.22
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.38
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	77435000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	73097000	usd
CY2023Q4	cnta	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	14440000	usd
CY2022Q4	cnta	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	15624000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	10488000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	7174000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3246000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1467000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	105609000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	97362000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	73239000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	93850000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	32370000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3512000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	2723000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	29647000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	3512000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-20600000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	44800000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-187643000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-173476000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	11502000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-43478000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-176141000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-216954000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1237000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1575000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-26272000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-2464000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	233000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	534000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-256000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-392000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	2000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-25056000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-747000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.24
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.19
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.04
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.02
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.02
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.01
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.10
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.07
CY2023	cnta	Effective Income Tax Rate Reconciliation Losses Surrendered For Tax Incentive Percent EffectiveIncomeTaxRateReconciliationLossesSurrenderedForTaxIncentivePercent	-0.28
CY2022	cnta	Effective Income Tax Rate Reconciliation Losses Surrendered For Tax Incentive Percent EffectiveIncomeTaxRateReconciliationLossesSurrenderedForTaxIncentivePercent	-0.07
CY2023	cnta	Effective Income Tax Rate Reconciliation Non Taxable Research And Development Percent EffectiveIncomeTaxRateReconciliationNonTaxableResearchAndDevelopmentPercent	0.03
CY2022	cnta	Effective Income Tax Rate Reconciliation Non Taxable Research And Development Percent EffectiveIncomeTaxRateReconciliationNonTaxableResearchAndDevelopmentPercent	0.01
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.01
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.01
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.02
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.03
CY2023	cnta	Effective Income Tax Rate Reconciliation Unrecognized Tax Benefits Percent EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent	-0.01
CY2022	cnta	Effective Income Tax Rate Reconciliation Unrecognized Tax Benefits Percent EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent	0
CY2023	cnta	Effective Income Tax Rate Reconciliation Return To Provision Adjustments Percent EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsPercent	0.02
CY2022	cnta	Effective Income Tax Rate Reconciliation Return To Provision Adjustments Percent EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsPercent	0
CY2023	cnta	Effective Income Tax Rate Reconciliation Release Of Us Valuation Allowance Percent EffectiveIncomeTaxRateReconciliationReleaseOfUSValuationAllowancePercent	0.15
CY2022	cnta	Effective Income Tax Rate Reconciliation Release Of Us Valuation Allowance Percent EffectiveIncomeTaxRateReconciliationReleaseOfUSValuationAllowancePercent	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.06
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.23
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.14
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2614000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2614000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2600000	usd
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	dei	Auditor Name AuditorName	KPMG LLP
CY2023	dei	Auditor Location AuditorLocation	Boston, MA
CY2023	dei	Auditor Firm AuditorFirmId	185

Files In Submission

Name	View Source	Status
0001847903-24-000054-index-headers.html	Edgar Link	pending
0001847903-24-000054-index.html	Edgar Link	pending
0001847903-24-000054.txt	Edgar Link	pending
0001847903-24-000054-xbrl.zip	Edgar Link	pending
a20231231ex231kpmgconsent.htm	Edgar Link	pending
a20231231exhibit311.htm	Edgar Link	pending
a20231231exhibit312.htm	Edgar Link	pending
a20231231exhibit321.htm	Edgar Link	pending
a20231231exhibit322.htm	Edgar Link	pending
centessa-redactedemploymen.htm	Edgar Link	pending
centessa-redactedserviceag.htm	Edgar Link	pending
cnta-20231231.htm	Edgar Link	pending
cnta-20231231.xsd	Edgar Link	pending
cnta-20231231_g1.jpg	Edgar Link	pending
cnta-20231231_g10.jpg	Edgar Link	pending
cnta-20231231_g11.jpg	Edgar Link	pending
cnta-20231231_g12.jpg	Edgar Link	pending
cnta-20231231_g13.jpg	Edgar Link	pending
cnta-20231231_g14.jpg	Edgar Link	pending
cnta-20231231_g15.jpg	Edgar Link	pending
cnta-20231231_g16.jpg	Edgar Link	pending
cnta-20231231_g2.jpg	Edgar Link	pending
cnta-20231231_g3.jpg	Edgar Link	pending
cnta-20231231_g4.jpg	Edgar Link	pending
cnta-20231231_g5.jpg	Edgar Link	pending
cnta-20231231_g6.jpg	Edgar Link	pending
cnta-20231231_g7.jpg	Edgar Link	pending
cnta-20231231_g8.jpg	Edgar Link	pending
cnta-20231231_g9.jpg	Edgar Link	pending
ex21cnta_subs.htm	Edgar Link	pending
ex97cntacompensationclawba.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
cnta-20231231_def.xml	Edgar Link	unprocessable
cnta-20231231_lab.xml	Edgar Link	unprocessable
cnta-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cnta-20231231_htm.xml	Edgar Link	completed
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
cnta-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CNTA
Centessa Pharmaceuticals plc Stock $cnta

2024 Q1 Form 10-K Financial Statement

#000184790324000054 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNTA Centessa Pharmaceuticals plc Stock $cnta

2024 Q1 Form 10-K Financial Statement

#000184790324000054 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNTA
Centessa Pharmaceuticals plc Stock $cnta